Includes Information about Pharmacotherapeutic of ASTHMA all details about etiology, Pathophysiology, pharmacology, treatment, current clinical trials on ASTHMA etc.

1. ASTHMA
Guided By
Dr. S . D Patil
Dept. Of Pharmacy Practice
RCPIPER, SHIRPUR
Presented By
Madhukar Thagnar
Dept. Of Pharmacy Practice
RCPIPER, SHIRPUR
R. C. Patel institute of pharmaceutical education and research, Shirpur
1

2. DEFINITION
Asthma is a chronic inflammatory disease of
the airways characterized by hyper
responsiveness, mucosal edema, and mucus
production.
It is a chronic lung disease that inflames and
narrows the airways.
2
(Ref. K.D. Tripathi)

3. 3
Ref. Slide share

4. 4
Ref. Slide share

5. TYPES OF ASTHMA
5

6. Hyper responsiveness
to inhalation of
specific allergen
such as pet dust,
house dust, mold,
pollen, food .
1. ALLERGIC /ATROPIC /
EXTRINSIC ASTHMA
6

7. Irritants in air not
related to allergies
such as air
pollution
2. NON ALLERGIC / NON
ATOPIC / INTRINSIC
7

8. 3. ETI [exercise induced asthma]
mixed asthma
4. Cough variant asthma ;
Persistent Dry Cough
5. Nocturnal asthma : At Night
8
Ref. Slide share

9. Cough
Chest tightness
Wheezing
Dyspnoea.
SYMPTOMS

10. Diaphoresis(excessive sweating)
Tachycardia(increased H.R)
 Usual rise in pulse pressure
Allergic reactions founded as like rashes ,
edema .
ADDITIONALSYMPTOMS

11. RISK FACTORS
11

12. Risk factors for asthma include ;
 Family history
Allergy (strongest factor),
 chronic exposure to air-way irritants or allergens
 (E.G., Grass, weed pollens, mold, dust, or animals)
Common triggers for asthma symptoms and
(e.g., Pollutants, cold, heat, strong odours, smoke,
perfumes), exercise, stress or emotional upset, viral
respiratory tract infections, and gastroesophageal reflux.
Ref. Roger and walker Clinical pharmacy and therapeutics

13. 13
Ref. Slide share

14. CLINICAL MANIFESTATIONS
14

15. 15
Ref. Slide share

16. PATHOPHYSIOLOGY
16

17. 17
Ref. Google search

18. 18
Activation Of B
Cell
Increases Level
Of Ige
Binding Of Ige In
Mast Cells
Release Of
Histamines
Broncho
Constriction
Spasm Occurs
Increases
Hypersensitivity
Attack Of
Bronchial Asthma
Ref. Google search

19. ASSESSMENT AND
DIAGNOSTIC METHODS
19

20. • Family, environment, and occupational history is
essential.
• During acute episodes,
Sputum test
Blood test
spirometry–measures how fast can breathe out
Blood level of eosinophils and IgE
Chest X-ray.

21. MEDICAL MANAGEMENT
21

22.  the patient is instructed to identify and
avoid asthma triggers.
 If triggers cannot be avoided the patient
can use bronchodialators before exposure.
AVOIDANCE OF
TRIGGERS
22

23. PHARMACOLOGICAL THERAPY
23

24. 24

25. MEDICATIONS
1.LONG ACTING CONTROL
A. Inhaled Corticosteroid Medications-
Fluticasone, Budesonide, Mometasone, Beclomethasone
B. Leuketrine Modifiers-
Montelukast, Zafirlukast And Zileuton.
C. Long Term Beta Agonists-
Salmeterol And Formoterol
D. Methylxanthines-theophylline
E. Combination Inhalers- Fluticasone & Salmeterol
F. Cromolyn Sodium- Omalizumab
Ref. K.D. Tripathi

26. 2 QUICK RELIEF
A. SHORT-ACTING BETA2-ADRENERGIC AGONISTS-
Albuterol , levalbuterol ,metaproterenol , terbutaline
B. ANTICHOLINERGICS – Ipratropium bromide, ipratropium and
tiotropium.
C. ORAL & IV CORTICOSTEROIDS: Prednisolone
Prednisone,Prednisolone,Methylprednisolone,Dexamethasone.
D . LEUKOTRIENE MODIFIERS
INHIBITORS/ANTILEUKOTRIENES
Methylxanthines montelukast, zafirlukast and zileuton
26
Ref. K.D. Tripathi

27. NON PHARMACOLOGIC
INVENTIONS
 Patient And Family Education To Understand
The Disease, And To Foster Self-confidence
And Fitness.
 Avoid Smoking.
 Avoid “Identified Cause” Where Possible
 Control Of Extrinsic Factors Which Cause
Allergy Like Pets, Moulds And Certain
Foodstuffs, Particularly In Childhood.
 Avoid Beta-blockers, Aspirin And NSAIDS.
27
Ref. K.D. Tripathi

28. NEW DRUGS IN CLINICAL
TRIALS
(PHASE 3)
28

29. 1. A Study to Evaluate the Effect of
Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or
Relvar® Ellipta® DPI on Ventilation Heterogeneity in
Asthma
Fluticasone Fluticasone
furoate
Formoterol Vilanterol
TITLE
Ref. https://clinicaltrials.gov/ct2/show/NCT02194699

30. 2. A Study to Compare the Efficacy of Fluticasone
Furoate/Vilanterol Inhalation Powder With Usual
Inhaled Corticosteroids (ICS)/Long Acting Beta
Agonists (LABA) in Persistent Asthma
Budesonide Formoterol
Fluticasone furoate Salmeterol
Fluticasone
propionate
Vilanterol
30
Ref. https://clinicaltrials.gov/ct2/show/NCT02194699

31. REFERENCE
www.slideshare.com
K D Tripathi Essentials of medical pharmacology
,8th edition , jaypee Brothers Medical publication
Roger and walker Clinical pharmacy and
therapeutics –churchill livingstone publication
Drugs in clinical trials phase 3
https://clinicaltrials.gov/ct2/show/NCT02194699

32. THANK
YOU !
32